Aclarion, Inc.
- Open
- 2.64
- Day high
- 2.86
- Day low
- 2.64
- Prev close
- 2.71
- Volume
- 40K
- Mkt cap
- $7M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.4
- P/S
- 93.3
- Yield
- —
- Per share
- —
- ▲Insiders net buying $51K over the last 3 months (4 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions accumulating (13F)
Aclarion, Inc. (ACON) is a Healthcare company listed on NASDAQ. The stock is down 62% over the past year. Over the trailing 3 months, insiders filed 4 open-market buys and 0 sales (SEC Form 4).
Aclarion, Inc. (ACON) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ACON earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 21, 2026 | $-1.55 | $-9.32 | -501.3% | $21140 | -15.4% |
| Mar 18, 2026 | $-3.60 | $-2.01 | +44.2% | $75.7B | +378649613.7% |
| Nov 12, 2025 | $-2.64 | $-2.93 | -11.0% | $18942 | -0.3% |
| Aug 14, 2025 | $-2.26 | $-2.75 | -21.7% | $19319 | -35.6% |
| May 15, 2025 | $-1447.20 | $-9.32 | +99.4% | $18991 | -5.0% |
| Mar 27, 2025 | $-50.00 | $-1551.93 | -3003.9% | $10232 | — |
| Nov 14, 2024 | $-1621.62 | $-1351.35 | +16.7% | $14407 | -4.0% |
| Aug 14, 2024 | $-0.19 | $-1351.35 | -711136.8% | $10971 | +4.5% |
| May 15, 2024 | $-0.57 | $-3963.96 | -695331.6% | $10114 | +1.1% |
| Nov 14, 2023 | $-13024.80 | $-17297.30 | -32.8% | $19065 | -74.6% |
| Aug 25, 2023 | $-0.09 | $-25945.95 | -28828733.3% | $17072 | -65.9% |
| Feb 27, 2023 | $-911.20 | $-24463.39 | -2584.7% | $22520 | -2.1% |
ACON insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Bond Ryanofficer: Chief Strategy Officer | Grant | 55,000 | — |
| Jun 12, 2026 | Deitsch Stephendirector | Grant | 20,000 | — |
| Jun 12, 2026 | Neal David Kdirector | Grant | 20,000 | — |
| Jun 12, 2026 | Thramann Jeffrey Johndirector, officer: Executive Chairman | Grant | 100,000 | — |
| Jun 12, 2026 | Wesemann Williamdirector | Grant | 20,000 | — |
| Jun 12, 2026 | Ness Brentdirector, officer: Chief Executive Officer | Grant | 100,000 | — |
| Jun 12, 2026 | Gould Gregory Aofficer: Chief Financial Officer | Grant | 50,000 | — |
| Jun 12, 2026 | Breidbart Scottdirector | Grant | 20,000 | — |
| Jun 12, 2026 | Sequira Amanda Maedirector | Grant | 20,000 | — |
| May 12, 2026 | Neal David Kdirector | Buy | 2,500 | $3.10 |
| May 12, 2026 | Breidbart Scottdirector | Buy | 5,664 | $3.18 |
| May 11, 2026 | Ness Brentdirector, officer: Chief Executive Officer | Buy | 6,289 | $3.18 |
| May 8, 2026 | Wesemann Williamdirector | Buy | 1,562 | $3.30 |
| Dec 1, 2025 | Ness Brentdirector, officer: Chief Executive Officer | Buy | 10 | $6.20 |
| Sep 3, 2025 | Gould Gregory Aofficer: CFO | Grant | 17,000 | $7.15 |
Source: ACON SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full ACON insider & 13F page →Aclarion, Inc. company profile
Overview
Aclarion, Inc. (NASDAQ:ACON) is a healthcare technology company founded in 2008 and headquartered in San Mateo, California. Originally known as Nocimed, Inc., the company changed its name to Aclarion in December 2021 and went public in April 2022. The company specializes in developing software applications for magnetic resonance spectroscopy (MRS) technology, specifically targeting the diagnosis and treatment of degenerative spinal conditions. As a relatively young public company, Aclarion operates in the emerging field of medical imaging software, focusing on providing clinicians with advanced diagnostic tools to better understand and treat chronic back pain.
Business
Aclarion operates in the healthcare information services industry, developing specialized software for magnetic resonance spectroscopy (MRS) analysis. Magnetic resonance spectroscopy is an advanced medical imaging technique that extends beyond traditional MRI by analyzing the chemical composition of tissues at the molecular level. While standard MRI shows anatomical structures, MRS can detect specific biochemical markers that indicate tissue health and disease progression. The company's flagship product is the NOCISCAN-LS Post-Processor suite, which consists of two main components. The first component, NOCICALC-LS, is software that receives and processes MRS data specifically from spinal discs to calculate levels of degenerative pain biomarkers. These biomarkers are chemical indicators that can reveal the presence and severity of disc degeneration, which is a major cause of chronic lower back pain. The second component, NOCIGRAM-LS, serves as clinical decision support software that helps physicians interpret the biomarker data and make more informed treatment decisions. This technology addresses a significant challenge in spine care: the difficulty of accurately diagnosing the source of chronic back pain. Traditional imaging methods like X-rays and standard MRI can show structural problems but often cannot determine whether those structural issues are actually causing the patient's pain. Aclarion's MRS-based approach aims to provide objective, biochemical evidence of disc degeneration that correlates with pain symptoms, potentially leading to more targeted and effective treatments. The company operates as a single business segment focused entirely on this spinal disc analysis technology, with all revenue derived from the NOCISCAN-LS product suite.
Revenue model
Aclarion generates revenue primarily through product sales of its NOCISCAN-LS software suite to healthcare providers, including hospitals, imaging centers, and spine specialty clinics. The company's business model appears to be based on licensing its software to medical facilities that perform MRI scans and want to add advanced MRS analysis capabilities for spinal disc evaluation. The paying customers are healthcare institutions and medical practices that treat patients with chronic back pain and want to enhance their diagnostic capabilities. Given the company's early stage and relatively low revenue figures (approximately $46,000 in fiscal 2024), the customer base appears to be limited, suggesting the company is still in the early commercialization phase. Several factors could significantly impact Aclarion's margins and revenue potential. Positive factors include the growing prevalence of chronic back pain as populations age, increasing healthcare spending on diagnostic technologies, and the potential for the company's technology to reduce unnecessary surgeries by providing better diagnostic clarity. The shift toward precision medicine and evidence-based treatment decisions also favors technologies that provide objective biomarker data. Challenging factors include the lengthy adoption cycles typical in healthcare technology, where hospitals and clinics are often slow to adopt new diagnostic tools due to regulatory requirements, training needs, and budget constraints. The company must also navigate complex healthcare reimbursement systems, as insurance coverage for new diagnostic technologies can be uncertain. Competition from established medical imaging companies with greater resources and market presence poses another significant challenge. Additionally, the company's cash burn rate and need for ongoing clinical validation studies to prove the efficacy of its technology create financial pressures that could limit its ability to scale operations effectively.
Competitive moat
Aclarion's competitive moat appears to be relatively narrow at this stage of development. The company's primary competitive advantage lies in its specialized focus on MRS analysis for spinal disc degeneration, an area where few companies have developed dedicated solutions. The technical expertise required to develop software that accurately processes MRS data and identifies relevant biomarkers creates some barriers to entry, as does the regulatory pathway required for medical device software. However, this moat is not particularly strong or durable. The company operates in a highly competitive medical technology landscape where large, well-established players like Siemens Healthineers, GE Healthcare, and Philips have significantly greater resources to develop competing technologies. These companies already have established relationships with hospitals and imaging centers, making customer acquisition challenging for a small company like Aclarion. The regulatory environment provides some protection, as competitors would need to invest time and resources to obtain similar regulatory approvals. Additionally, the company's intellectual property portfolio may offer some defensive advantages, though the strength and breadth of these patents are not clearly established from available information. Potential disruption could come from several sources: larger medical imaging companies developing their own MRS analysis software, artificial intelligence and machine learning technologies that could provide alternative approaches to pain diagnosis, or entirely different diagnostic modalities that prove more effective or cost-efficient. The company's small size and limited resources make it vulnerable to being outmaneuvered by competitors with deeper pockets and broader market access. Without significant technological breakthroughs or strategic partnerships, Aclarion's competitive position remains precarious in the face of well-funded industry incumbents.
Risks & safety
The margin of safety for Aclarion appears extremely limited, presenting significant financial risks for investors. • Cash burn and solvency risk: The company burned approximately $5.6 million in free cash flow during fiscal 2024 while generating only $46,000 in revenue. With $14.8 million in cash as of Q1 2025, the company has roughly 2-3 years of runway at current burn rates, assuming no revenue growth. • Debt level: Positive aspect - the company carries essentially no debt (debt-to-equity ratio of 0.0), eliminating immediate solvency concerns from debt obligations. • Valuation metrics: Current ratio of 21.7 indicates strong short-term liquidity following what appears to be a recent capital raise. However, traditional valuation metrics are largely meaningless given minimal revenue and substantial losses. • Other considerations: The company's $4 million market capitalization represents a significant discount to its cash position, suggesting the market has little confidence in the business model's viability. The dramatic decline in stock price from over $100,000 per share in 2022 to under $7 currently (adjusting for stock splits) reflects severe investor skepticism about the company's prospects.
Recent development
Based on available financial data, Aclarion's recent development appears focused on the continued commercialization of its NOCISCAN-LS technology suite. The company has maintained consistent but minimal revenue generation, with annual revenues ranging from approximately $45,000 to $75,000 over the past three years, suggesting limited market traction despite ongoing efforts. The most significant recent development appears to be a substantial capital raise that occurred between Q4 2024 and Q1 2025, as evidenced by the dramatic increase in cash and short-term investments from $454,000 to $14.8 million. This funding likely provides the company with additional runway to continue product development and market expansion efforts. Revenue patterns show some volatility quarter-to-quarter, which is typical for early-stage companies with limited customer bases. The company's consistent high cash burn rate of $5-6 million annually suggests ongoing investment in research and development, regulatory activities, and commercialization efforts. However, the lack of meaningful revenue growth over multiple years indicates that the company has not yet achieved significant market acceptance for its technology, despite continued investment in the business.
ACON company profile · for informational purposes only — not investment advice.
Track ACON with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free